OSU-2S/sorafenib synergistic antitumor combination against hepatocellular carcinoma: The role of PKCδ/p53

• Asıl Yazarlar: Hany A Omar (Yazar), Mai F. Tolba (Yazar), Jui-Hsiang Hung (Yazar), Taleb H AlTel (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2016-11-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high doses limit the clinical application of sorafenib and strongly recommend its combination with other agents aiming at ameliorating it...